Science2 publishersIndependently confirmed2 min readPublished
Optogenetic gene therapy improves light sensitivity in 7 of 10 people blinded by retinitis pigmentosa
Optogenetic gene therapy restored some vision to people blinded by retinitis pigmentosa in a small NEJM trial. Seven of 10 participants improved in light sensitivity, Science News reported, though the goggle-aided sight let none of them read words or see faces.
The Scientist · Science desk
What happened
- Researchers injected genes for ChrimsonR, a light-sensitive algae protein, into each participant's worse-seeing eye, making its retinal ganglion cells respond to amber light.
- Custom goggles carry a camera that detects changes in brightness and projects them onto the retina as pulses of amber light.
- Four of the eight participants who completed behavioral testing could find a doorway or follow a line while wearing the goggles.
Compiled by The ScientistSomething wrong?How this is made
Why it matters
- capability Outside the subset whose mutation qualifies for existing gene therapy, retinitis pigmentosa care only slows the loss; moving light sensing into surviving ganglion cells gives the rest a candidate route to regaining some function.
- cost The functional gains were measured with custom goggles on, so the treatment as tested is a gene injection paired with a camera device, and a patient needs both to benefit.
- constraint Patients whose retina-to-brain connection is damaged fall outside the approach, so eligibility will depend on the optic nerve as well as the retina.
The 7-of-10 figure counts improved light sensitivity [1]. The behavioral test is a closer proxy for usable sight, and it ran on fewer people. Four successes out of eight tested [12] is half of that group [19] and 40 percent of the ten treated [20]. Two participants did not complete behavioral testing [21]. The news reports do not say why, and they do not describe a control group.
With ten people, each participant moves the response rate by 10 percentage points [16], so the 70 percent is a rough estimate [17]. In my view it is still enough to call the result repeatable. The study it builds on was a single case: a 2021 report of one blind man who could see and count objects [7].
The design works around the damage instead of repairing it. Retinitis pigmentosa kills the retina's light-sensing cells [2], so the therapy gives light sensitivity to the ganglion cells that normally relay visual signals to the brain [8]. Everything past those cells still has to work. The approach needs a working optic nerve, according to coauthor José-Alain Sahel, an ophthalmologist at the University of Pittsburgh [14]. When the retina's connection to the brain is damaged, it cannot restore vision [14].
Botond Roska, a neuroscientist at the Institute of Molecular and Clinical Ophthalmology Basel, described the result as a proof of concept that optogenetics can bring back some visual activity and object sensitivity [9][15]. His group hopes to work on reading and faces next [13].
The people this is aimed at are usually diagnosed in childhood or early adolescence and are often legally blind by young adulthood, STAT reported [4]. The paper appeared in the New England Journal of Medicine on Wednesday, October 7 [1][6], two days after pioneering optogenetics work won the 2026 Nobel Prize in Physiology or Medicine [3][18].
What to watch
- A full trial report explaining why two of the ten participants missed behavioral testing and whether any untreated comparison was used.
- Whether Roska's group shows reading or face recognition in a later cohort, a goal no participant in this trial reached.
- Whether light sensitivity in the treated eyes holds up over longer follow-up.